Skip to main content
SpringerLink
Log in

Antipsychotic Drugs and Interactions

Implications for Criminal and Civil Litigation

  • Chapter
Handbook of Drug Interactions

Part of the book series: Forensic Science and Medicine ((FSM))

Abstract

Antipsychotics include two general classes of drugs. Traditional antipsychotics are thought to act by exerting effects principally on the dopamine neurotransmitter system (1). The traditional antipsychotics became known to many as neuroleptics based on their frequent effects of substantially slowing movement (1). Atypical antipsychotics, designed in laboratories to provide psychotic symptom relief without movement problems, affect other neurotransmitter systems (2), and present other potential concerns.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychology. Baltimore: Williams and Wilkins, 1994:940–960.

    Google Scholar 

  2. Stahl SM. “Hit-and-run” actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. J Clin Psychiatry 62(9):670–671 (2001).

    Article  PubMed  CAS  Google Scholar 

  3. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:2.

    Google Scholar 

  4. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:411–414.

    Google Scholar 

  5. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry. Baltimore: Williams & Wilkins, 1994:984.

    Google Scholar 

  6. Seeman P. Atypical antipsychotics: mechanism of action. Canadian J of Psychiatry 47(1): 27–38 (2000).

    Google Scholar 

  7. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:375.

    Google Scholar 

  8. Wirshing W. Movement disorders associated with neuroleptic treatment. J Clin Psychol 62(Suppl 21):15 (2001).

    CAS  Google Scholar 

  9. Sethi K. Movement disorders induced by dopamine blocking agents. Semin Neurol 21(1): 60 (2001).

    Article  Google Scholar 

  10. Kaufman DM. Clinical neurology for psychiatrists, 3rd ed. Philadelphia: Saunders, 1990: 368.

    Google Scholar 

  11. Wallis LA. Textbook of women’s health. Philadelphia: Lippincott-Raven, 1998.

    Google Scholar 

  12. Mamo D, Sweet R, Mulsant B, Rosen J, and Pollock BG. Neuroleptic-induced parkinsonism in Alzheimer’s disease. Psychiatric Annals 32(4):249–252 (2002).

    Google Scholar 

  13. Stahl S. Essential psychopharmacology, Cambridge, England: Cambridge University Press, 2000:408.

    Google Scholar 

  14. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry, 7th ed. Baltimore: Williams & Wilkins, 1994:896–897.

    Google Scholar 

  15. Kaufman DM. Clinical neurology for psychiatrists, 3rd ed. Philadelphia: Saunders, 1990: 379.

    Google Scholar 

  16. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry, 7th ed. Baltimore: Williams & Wilkins, 1994:950.

    Google Scholar 

  17. Matsumoto RR and Pouw B. Correlation between neuroloeptic binding to singam(1) and sigma(2): receptors and acute dystonic reactions. Eur J Pharmacol 401(2):155–160 (2000).

    Article  PubMed  CAS  Google Scholar 

  18. Velickovic M, Benabou R, and Brin MF. Cervical dystonia pathophysiology and treatment ontions. Drugs 61(13):1921–1943 (2001).

    Article  PubMed  CAS  Google Scholar 

  19. Csernansky JG and Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16(7):473–484 (2002).

    Article  PubMed  Google Scholar 

  20. Gorman JM, ed. The essential guide to psychiatric drugs. New York: St. Martins Press, 1990:218.

    Google Scholar 

  21. Holloman LC and Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 54(21):2461–2477 (1997).

    PubMed  CAS  Google Scholar 

  22. Lima AR, Soares-Weiser K, Bacaltchuk J, and Barnes TRE. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database System Review (1):CD001950 (2002).

    Google Scholar 

  23. Bernstein JG. Clinical psychopharmacology, 2nd ed. Littleton, CO: Library of Congress, 1984:162.

    Google Scholar 

  24. Siris S. Suicide and schizophrenia. J Psychopharm 15(2):127–135 (2001).

    Article  CAS  Google Scholar 

  25. Kaufman DM. Clinical neurology for psychiatrists, 3rd ed. Philadelphia: Saunders, 1990: 394.

    Google Scholar 

  26. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry, 7th ed. Baltimore: Williams & Wilkins, 1994:885.

    Google Scholar 

  27. Sethi K. Movement disorders induced by dopamine blocking agents. Semin Neurol 21(1): 59–68 (2001).

    Article  PubMed  CAS  Google Scholar 

  28. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35:S61-S66 (1999).

    Article  Google Scholar 

  29. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry, 7th ed. Baltimore: Williams & Wilkins, 1994:951.

    Google Scholar 

  30. Wirshing W. Movement disorders associated with neuroleptic treatment. J Clin Psychol 62(Suppl 21):15–18 (2001).

    CAS  Google Scholar 

  31. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:406.

    Google Scholar 

  32. Sethi K. Movement disorders induced by dopamine blocking agents. Semin Neurol 21(1): 61 (2001).

    Article  Google Scholar 

  33. Soares KV and McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database System Review (2):CD000209 (2000).

    Google Scholar 

  34. Llorca PM, Chereau I, Bayle FJ, et al. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17(3):129–138 (2002).

    Article  PubMed  Google Scholar 

  35. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:406.

    Google Scholar 

  36. Ghadirian AM, Annable L, Belanger MC, and Chouinard G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 57(1):22–28 (1996).

    PubMed  CAS  Google Scholar 

  37. Ayd F. Evaluating the interactions between herbal and psychoactive medications. Psychiatric Times December: 45–46 (2000).

    Google Scholar 

  38. Goldberg E, ed. The executive brain. New York: Oxford University Press, 2001:94.

    Google Scholar 

  39. Physicians’ desk reference, 57th ed. Montvale, NJ: Medical Economics Company, Inc., 2003 :1787.

    Google Scholar 

  40. Asarnow RF. Neurocognitive impairments in schizophrenia: a piece of the epigenetic puzzle. Eur Child Adolesc Psychiatry 8(Suppl 1):15–18 (1999).

    Google Scholar 

  41. Diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000:301.

    Google Scholar 

  42. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:370.

    Google Scholar 

  43. Kaplan H and Sadock B. Synopsis of psychiatry: behavioral sciences clinical psychology, 7th ed. Baltimore: Williams and Wilkins, 1994.

    Google Scholar 

  44. Knegtering H, Eijck M, and Hijsman A. Effects of antidepressants on cognitive functioning of elderly patients. Drugs Aging 5(3):192–199 (1994).

    Article  PubMed  CAS  Google Scholar 

  45. Bernstein JB. Clinical psychopharmocology, 2nd ed. Boston: John Wright, 1984.

    Google Scholar 

  46. Kaplan H and Sadock B. Synopsis of psychiatry: behavioral sciences clinical psychology, 7th ed. Baltimore: Williams and Wilkins, 1994:945.

    Google Scholar 

  47. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:378.

    Google Scholar 

  48. Physicians’ desk reference, 57th ed. Montvale, NJ: Medical Economics Company, Inc., 2003:1789.

    Google Scholar 

  49. Turrone P, Kapur S, Seeman MV, and Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159(1):133–135.

    Article  Google Scholar 

  50. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry, 7th ed. Baltimore: Williams & Wilkins, 1994:948.

    Google Scholar 

  51. Physicians’ desk reference, 57th ed. Montvale, NJ: Medical Economics Company, Inc., 2003:1053, 1299, 1417, 1651–1652.

    Google Scholar 

  52. Allison DB, Mentore JL, and Heo M. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696 (1999).

    PubMed  CAS  Google Scholar 

  53. McIntyre R. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychol 63(3):15–20 (2002).

    CAS  Google Scholar 

  54. Haupt D and Newcomer J. Hyperglycemia and antipsycotic medications. J Clin Psychol 62(27):15–26 (2001).

    CAS  Google Scholar 

  55. Jin H, Meyer JM, and Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14(1):59–64 (2002).

    Article  PubMed  Google Scholar 

  56. Stahl S. Essential psychopharmacology, Cambridge, England: Cambridge University Press, 2000:415–421.

    Google Scholar 

  57. Kaplan H, Sadock B, and Grebb J. Synopsis of psychiatry: behavioral sciences clinical psychiatry, 7th ed. Baltimore: Williams & Wilkins, 1994:947.

    Google Scholar 

  58. Jusic N and Lader M. Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 165:787–791 (1994).

    Article  PubMed  CAS  Google Scholar 

  59. Ray W. Arch Gen Psychiatry 58(11).1168–1170 (2001).

    Google Scholar 

  60. Markowitz JS, Wells BG, and Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 29:603–609 (1995).

    PubMed  CAS  Google Scholar 

  61. Devane C and Markowitz J. Avoiding psychotropic drug interactions in the cardiac patient. TEN 3(5):67–71 (2001).

    Google Scholar 

  62. Grohman R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology (Berl) 99:101–104 (1989).

    Article  Google Scholar 

  63. Killian JG, Kerr K, Lawrence C, and Celermajer DS, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354:1841–1845 (1999).

    Article  Google Scholar 

  64. DeVane CL and Nemeroff CB. Drug interactions in psychiatry. Primary Psychiatry 7(10): 67 (2000).

    Google Scholar 

  65. Haddad PM and Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62(11):1649–1671 (2002).

    Article  PubMed  CAS  Google Scholar 

  66. Menkes DB and Knight JC. Cardiotoxicity and prescription of thioridazine in New Zealand. Aust N Z J Psychiatry 36(4):492–498 (2002).

    Article  PubMed  Google Scholar 

  67. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for ziprasidone hydrochloride. July 19, 2000.

    Google Scholar 

  68. Glassman AH and Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsades de pointes and sudden death. Am J Psychiatry 158(11):1774–1782 (2001).

    Article  PubMed  CAS  Google Scholar 

  69. Young D. Black-box warning for droperidol surprises pharmacists. Am J Health Syst Pharm 59(6):494, 497, 502–504 (2002).

    Google Scholar 

  70. Glassman AH and Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsades de pointes and sudden death. Am J Psychiatry 158(11):1774–1782 (2001).

    Article  PubMed  CAS  Google Scholar 

  71. Smego RA and Durack DT. The neuroleptic malignant syndrome. Arch Intern Med 142: 1183–1185 (1982).

    Article  PubMed  Google Scholar 

  72. Friedman JH. Recognition and treatment of the neuroleptic malignant syndrome. Curr Opin Neurol 1:310–311 (1988).

    Google Scholar 

  73. Reeves RR, Torres RA, Liberto V, and Hart RH. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 22(5):641–644 (2002).

    Article  PubMed  Google Scholar 

  74. Sing KJ, Ramaekers GM, and Van Harten PN. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 159(1):149–150 (2002).

    Article  PubMed  Google Scholar 

  75. Blum MW, Siegel AM, Meier R, et al. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication. Eur Neurol 46(3):158–160 (2001).

    Article  PubMed  CAS  Google Scholar 

  76. Aboraya A, Schumacher J, Abdalla E, LePage J, et al. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 98(2):63–65 (2002).

    PubMed  Google Scholar 

  77. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:540.

    Google Scholar 

  78. Clayton AH. Reconstruction and assessment of sexual dysfunction associated with depression. J Clin Psychiatry 62(Suppl 3):5–9 (2001).

    Article  PubMed  Google Scholar 

  79. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:542.

    Google Scholar 

  80. Compton MT and Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry 62(5):362–366 (2001).

    Article  PubMed  CAS  Google Scholar 

  81. Bernstein JB. Clinical psychopharmocology, 2nd ed. Boston: John Wright, 1984.

    Google Scholar 

  82. Pacia SV and Devinsky O. Clozapine-related seizures: experience with 5,629 patients neurology. Neurology 44(12):2247–2249 (1994).

    Article  PubMed  CAS  Google Scholar 

  83. Stahl S. Essential psychopharmacology. Cambridge, England: Cambridge University Press, 2000:207.

    Google Scholar 

  84. DeVane CL and Nemeroff C. Primary Psychiatry. 7(10):(2000).

    Google Scholar 

  85. Jibson M and Tandon R. An overview of antischizophrenic medications. CNS News Special Edition, December: 49–54 (2001).

    Google Scholar 

  86. Kaplan H and Sadock B. Synopsis of psychiatry: behavioral sciences clinical psychology, 7th ed. Baltimore: Williams and Wilkins, 1994:940–960.

    Google Scholar 

  87. Weber S. Drug interactions with antidepressants. CNS News February: 27–34 (2002).

    Google Scholar 

  88. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, and Christodoulou GN. Toxic interaction between risperidone and clozapine: A case report. Prog Neuropsychopharm Biol Psychiatry 26(2):407–409 (2002).

    Article  Google Scholar 

  89. Mental fitness physician resource series. Primary Psychiatry November: 36–37 (2000).

    Google Scholar 

  90. Grohman R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology 99:101–104 (1989).

    Article  Google Scholar 

  91. Mental fitness physician resource series. Primary Psychiatry November: 36 (2000).

    Google Scholar 

  92. DeVane CL and Nemeroff CB. Drug Interactions in psychiatry. Primary Psychiatry 7(10): 66 (2000).

    Google Scholar 

  93. Modai I, Hirschmann S, and Rava A. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 20(3):525–327 (2000).

    Article  Google Scholar 

  94. Kaplan H and Sadock B: Synopsis of psychiatry behavioral sciences clinical psychology, 7th ed. Baltimore: Williams and Wilkins, 1994.

    Google Scholar 

  95. DeVane CL and Nemeroff CB. Quetiapine drug interactions. Primary Psychiatry 7(10): (2000).

    Google Scholar 

  96. Greenblatt D. Symposium, American Association for Geriatric Psychiatry, 2001 annual meeting, San Francisco, CA.

    Google Scholar 

  97. Pies R. Geriatric psychopharmacology. Am Fam Physician 28(4):171–176 (1983).

    PubMed  CAS  Google Scholar 

  98. Pollock BG. Recent developments in drug metabolism of interest to psychiatrists. Harv Rev Psychiatry 2(4):204–213 (1994).

    Article  PubMed  CAS  Google Scholar 

  99. Tsunoda SM, Harris RZ, Mroczkowski PJ, and Benet LZ. Preliminary evaluation of progestins as inducers of cytochrome 3A4 activity in post-menopausal women. J Clin Pharmacology 38:1137–1143 (1998).

    CAS  Google Scholar 

  100. Tamminga WJ, Werner J, Oostehuis B, Wieling J, Wilffert Bde Liej LFMH, de Zeeuw RA, and Jonkman JHG, CYP2D6 and CYP2C19activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Euro J Clin Pharmacol 55(3):177–184 (1999).

    Article  CAS  Google Scholar 

  101. Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychol 60(Supp 12):43–46 (1999).

    CAS  Google Scholar 

  102. Perkins v United States 228 F 408 (1915).

    Google Scholar 

  103. Lexsee 73 ALR 3d 195; 2001, West Group.

    Google Scholar 

  104. Teeters y Commonwealth 310 Ky 546, 221 SW2d 85 (1949).

    Google Scholar 

  105. Wyngaarden JB, Smith LH, and Bennett JC. Cecil textbook of medicine. Philadelphia: Saunders, 1992.

    Google Scholar 

  106. Meyer PS, Bond GR, and Tunis SL. Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. J Clin Psychiatry 63(2):108–116 (2002).

    Article  PubMed  Google Scholar 

  107. Grohman R. Adverse effects of clozapine. Psychopharmacology 99(Suppl):S101-S104 (1989).

    Article  Google Scholar 

  108. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, and Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 61(5):382–386 (2000).

    Article  PubMed  CAS  Google Scholar 

  109. Higuchi H, Kamata M, Yoshimoto M, Shimisu T, and Hishikawa Y. Panic attacks in patients with chronic schizophrenia: a complication of long-term neuroleptic treatment. Psychiatry Clin Neurosci 53(1):91–94 (1999).

    Article  PubMed  CAS  Google Scholar 

  110. Physicians’ desk reference, 57th ed. Montvale, NJ: Medical Economics Company, Inc., 2003:1651–1652.

    Google Scholar 

  111. Gillenwater D and McDaniel J. Rational psychopharmacology for patients with HIV infection and AIDS. Psychiatric Annals 31(1):28–32 (2001).

    Google Scholar 

  112. Safdar A and Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 17(3):531–570 (2001).

    Article  PubMed  CAS  Google Scholar 

  113. Kaplan H and Sadock B. Synopsis of psychiatry: behavioral sciences clinical psychology, 7th ed. Baltimore: Williams and Wilkins, 1994:934.

    Google Scholar 

  114. Welch J, Manschreck T, and Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 6(3):250–256 (1994).

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michael Welner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harris County Medical Examiner Office, Houston, TX, USA

    Ashraf Mozayani PharmD, PhD

  2. University of Miami School of Medicine, Miami, FL, USA

    Lionel P. Raymon PharmD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Welner, M. (2004). Antipsychotic Drugs and Interactions. In: Mozayani, A., Raymon, L.P. (eds) Handbook of Drug Interactions. Forensic Science and Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-654-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-654-6_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-424-1

  • Online ISBN: 978-1-59259-654-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation